Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension Quantum Genomics…
Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America
Quantum Genomics has granted an exclusive license to Biolab Sanus Pharmaceutical to develop and commercialize…
Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update
The financial statements for the first half of 2019 reflect operating results of -€5.3 million,…
Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure
“The analysis of NEW-HOPE, Quantum Genomics’ Phase IIb study of firibastat in hypertension, has demonstrated…
Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension
“Currently, 150 million people around the globe struggle with difficult-to-control or treatment-resistant arterial hypertension, and…